You are here
Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune Regulation
CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that its scientific founder, Dr. James P. Allison was awarded the 2018 Nobel Prize in Physiology or Medicine for the discovery of cancer therapy by inhibition of negative immune regulation.
“On behalf of the whole Jounce team, I want to take the opportunity to congratulate Jim on this historic recognition and honor. Since our founding, Jounce has benefited tremendously from his leadership, expertise and dedication to cancer immunotherapy and this award is a testament to all that he has accomplished,” said Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics. “Jim played a fundamental role in ushering in the era of cancer immunotherapy, including his contributions to the understanding of the basic science of CTLA-4. Additionally, the identification of ICOS as a therapeutic approach in immuno-oncology led to the discovery and development of Jounce’s lead product candidate, JTX-2011.”
Additional information regarding Dr. James P. Allison’s biography and award can be found here.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently conducting the Phase 1/2 ICONIC trial. For more information, please visit www.jouncetx.com.
Jounce Therapeutics, Inc.
The Yates Network